Constellation Pharmaceuticals competitors

Dr. Fouse serves as President and Chief Operating Officer. She assumed that role on March 1, 2016. In February 2016, Dr. Fouse was elected to the Board of Directors. Previously she was President, Global Hematology and Oncology since July 2014. Dr. Fouse joined the Company in September 2010 as Senior Vice President and Chief Financial Officer and became Executive Vice President and Chief Financial Officer in February 2012. Before Celgene, Dr. Fouse served as Chief Financial Officer of Bunge Limited, a leading global agribusiness and food company (Bunge), starting in July 2007. Before Bunge, Dr. Fouse was at Alcon Laboratories serving as Senior Vice President, Chief Financial Officer, and Head of Corporate Strategy at Alcon Laboratories between 2002 and 2007. Dr. Fouse was the Chief Financial Officer at Swissair Group from 2001 to 2002. Dr. Fouse held a variety of senior finance positions at Nestlé S.A. from 1993 to 2001, including serving as Group Treasurer of Nestlé from 1999 to 2001. Dr. Fouse also worked in finance at Alcon from 1986 to 1993 and held several positions, including Manager Corporate Investments and Domestic Finance. Earlier in her career, she worked at Celanese Chemical and LTV Aerospace and Defense. Dr. Fouse earned a B.A. and an M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington. Dr. Fouse also serves as a member of the Board of Directors of Dick’s Sporting Goods (chairperson of the audit committee) and Perrigo Company (member of the audit committee), both NYSE-listed companies.

• CEO tasked with setting the strategic direction for development stage biotech entity and raising the capital to advance development of both pre-clinical and clinical stage new drug candidates. •Strong communicator who has effectively represented Pfizer, UCB, Celtaxsys and Innovative Med Concepts to the investment community. •Top performing senior executive with proven track record of achievement including managing $1.5+B P&L, leading and developing people, delivering profitable growth and driving operational improvement in all regions of the world (ie. US, EU, LATAM, APAC, AfME). •Executive Committee member charged with setting the strategic direction for the transformation of UCB’s $4B+ global, specialty company (stock accretion from.19 € to 50+ € during tenure). •Extensive experience managing R&D programs and portfolio investments and improving the value of future pipeline at Pfizer, UCB, Celtaxsys and Innovative Med Concepts. •Experience maximizing in-market performance of both ethical (large and small molecule, prescription and in-office utilization) and OTC product portfolios. Notable launch experience includes world-class brands such as Lipitor, Zoloft, Aricept, Viagra, Celebrex, Lyrica, Rebif, Cimzia, Vimpat and Sutent.